Sotatercept
An activin signalling inhibitor for pulmonary arterial hypertension.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 1, 2, 2, 12, 8.
All papers from the last 12 months
128 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Sotatercept in Pediatric Pulmonary Hypertension: Experience from the Pediatric Pulmonary Hypertension NetworkChest2026 Oct 5PMID 42833549
- On the differential hemodynamic effects of prostacyclins and sotaterceptJ Heart Lung Transplant2026 OctPMID 42400583
- A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectivesSemin Oncol2026 OctPMID 42385497
- What sotatercept can teach us about the right ventricle in pulmonary arterial hypertensionJ Heart Lung Transplant2026 OctPMID 42364793
- Is reduced right ventricular power after sotatercept beneficial?J Heart Lung Transplant2026 OctPMID 42320807
- Haemodynamic responses to sotatercept and parenteral prostacyclins in pulmonary arterial hypertension patientsJ Heart Lung Transplant2026 OctPMID 42229625
- Beyond pulmonary arterial hypertension: sotatercept across the advanced heart failure and transplant continuumFront Transplant2026PMID 42871017
- Managing High-Output Heart Failure Secondary to Prostacyclin Analog and Sotatercept Toxicity in Pulmonary Arterial HypertensionJACC Case Rep2026 Sep 29PMID 42814053
- Sotatercept Improves Right Heart Mechanics Despite Reduced Myocardial Contractility in Pulmonary Arterial Hypertension: A Prospective Exercise Hemodynamic StudyCirculation2026 Sep 22PMID 42770225
- Sotatercept in Pediatric Pulmonary Hypertension: Promising Hemodynamic Findings, but Are We Extrapolating Too Far?Pediatr Cardiol2026 Sep 18PMID 42760440
More pulmonology trends
All specialties →Antifibrotics in pulmonary fibrosis
Nintedanib, pirfenidone and newer antifibrotics.
Biologics in severe asthma
Biologic therapies for severe asthma.
Key point: Biologic choice in adult severe asthma can be impacted by quality of life impairment, lung function, exacerbation frequency, oral corticosteroid use, endotype, biomarkers and comorbidities.
Lung cancer screening
Low-dose CT screening for lung cancer.
Key point: Low-dose CT screening reduces lung cancer death risk by at least 21% and should be offered to people aged 50–75 with at least 20 pack-years.
E-cigarettes and the lungs
Respiratory effects of vaping and e-cigarettes.
Interstitial lung abnormalities
Incidental interstitial changes on CT and their significance.
Ensifentrine
An inhaled PDE3/PDE4 inhibitor for COPD.
Key point: Ensifentrine significantly improved lung function, symptoms and quality of life versus placebo in Chinese individuals with COPD, with similar adverse event rates.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
sotatercept[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.